Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study

EClinicalMedicine, Journal Year: 2024, Volume and Issue: 74, P. 102709 - 102709

Published: July 3, 2024

Rare genetic obesity commonly features early-onset obesity, hyperphagia, and therapy-resistance to lifestyle interventions. Pharmacotherapy is often required treat hyperphagia induce weight loss. We describe clinical outcomes of glucagon-like peptide-1 analogue liraglutide or naltrexone-bupropion treatment in adults with molecularly confirmed (MCGO) highly suspected for without definite diagnosis (HSGO).

Language: Английский

---

Lycium chinense Mill Induces Anti-Obesity and Anti-Diabetic Effects In Vitro and In Vivo

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 8572 - 8572

Published: Aug. 6, 2024

This study investigated the effects of Lycium chinense Mill (LCM) extract on obesity and diabetes, using both in vitro high-fat diet (HFD)-induced mouse models. We found that LCM notably enhanced glucagon-like peptide-1 (GLP-1) secretion NCI-h716 cells from 411.4 ± 10.75 pg/mL to compared NT (78.0 0.67 pg/mL) without causing cytotoxicity, implying involvement Protein Kinase A C (PKA C) AMP-activated protein kinase (AMPK) its action mechanism. also decreased lipid droplets lowered expression adipogenic lipogenic indicators, such as Fatty Acid Synthase (FAS), Acid-Binding 4 (FABP4), Sterol Regulatory Element-Binding 1c (SREBP1c), indicating suppression adipocyte differentiation accumulation. administration HFD mice resulted significant weight loss (41.5 3.3 g) group (45.1 1.8 g). In addition, improved glucose tolerance serum profiles demonstrated ability counteract obesity-related metabolic issues. Additionally, exhibited hepatoprotective properties by reducing hepatic accumulation diminishing white adipose tissue mass size, thereby demonstrating effectiveness against steatosis hypertrophy. These findings show can be efficiently used a natural material treat providing new approach for remedial therapeutic purposes.

Language: Английский

---

Perioperatives Management adipöser Patienten im Rahmen der elektiven Hüft- und Knieendoprothetik

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Adipositas ist eine weltweit wachsende Gesundheitskrise, die immer jüngere Altersgruppen betrifft und damit Endoprothetik vor neue Herausforderungen stellt. Viele Autoren sind aufgrund erhöhter Komplikationsraten in diesem Kollektiv der Meinung, dass bei Patienten mit einem Body-Mass-Index (BMI) von über 40 Probleme Vorteile Operation überwiegen ein Aufschieben bis zu einer signifikanten Gewichtsreduktion erfolgen sollte. Für systematische Literaturrecherche wurden elektronischen Datenbanken PubMed, Embase, Web of Science Cochrane Library Dezember 2023 durchsucht. 49 relevante Artikel identifiziert. Vorab definierte Fragestellungen anhand Literatur beantwortet. In Konsensmeeting wurde Evidenzgrad für Empfehlung definiert. Adipöse ab BMI ≥ 30 haben 3fach erhöhtes perioperatives Risiko, insbesondere Infektionen mechanische Komplikationen. Zudem technische Durchführung Operationen adipösen ihrer Körperfülle erschwert, was höheres Risiko Implantatfehlpositionierungen zur Folge hat. Trotz dieser Risiken profitieren adipöse ähnlich wie Normalgewichtige Operationen, vergleichbaren Verbesserungen Funktion Lebensqualität. Eine präoperative Gewichtsabnahme kann das reduzieren, muss jedoch langfristig erfolgen, um negative Stoffwechseleffekte vermeiden. Bariatrische Chirurgie medikamentöse Therapien können helfen, aber ihre Auswirkungen auf perioperative noch nicht geklärt. Neben dem allem sorgfältige Diagnostik Behandlung Komorbiditäten adipöser Outcome entscheidend. endoprothetischen Gelenksersatz Normalgewichtige, Komplikationen, Implantatfehlpositionen. Vor sollte Diätberatung angestrebt werden. Geleichzeitig auch metabolische Status überprüfen, da Mangelernährung übergewichtigen häufiger vorkommt erhöhen kann. Wenn trotz Maßnahmen keine erreicht wird, erhöhtem durchgeführt werden, wobei Patient umfassend aufgeklärt den Entscheidungsprozess miteingebunden werden

---

Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: March 17, 2025

Abstract Aims Clinical trials have demonstrated the effectiveness of phentermine and topiramate combination in weight management. This research evaluated efficacy safety phentermine/topiramate extended release (ER) for management, focusing on alterations body metabolic parameters routine clinical practice. Materials Methods We retrospectively included people with obesity who initiated ER between January 2020 April 2023 at 10 tertiary hospitals South Korea. The study assessed changes 5–6 months those continued, 12 months, along parameters. Total was measured using calibrated electronic scales participants light indoor clothing. Results cohort 1839 patients (540 men 1299 women), a 5–6‐month continuation rate 48%. At mean reduction 7.9%, sex‐specific losses 7.1% 8.2% women. Over 56% achieved more than 5% loss, 23% exceeding 10% reduction. Younger participants, women moderate to severe exhibited pronounced loss compared older individuals mild obesity, respectively. Concurrently, treatment improved glucose regulation, lipid profiles decreased blood pressure: HbA1c by 0.4 ± 0.9%, low‐density lipoprotein (LDL) cholesterol 32 mg/dL systolic pressure 6 15 mmHg (all p < 0.001). Treatment well‐tolerated, 15% incidence adverse events like paresthesia, dry mouth insomnia. persisted (21%) experienced an average 9.6%, 65% surpassing loss. Conclusion suggests is effective option management Korean population, though long‐term adherence remains challenge.

Language: Английский

---

Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation

European Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: May 15, 2025

Abstract Background Most forms of obesity are associated with chronic diseases that remain a global public health challenge. Aims Despite significant advancements in understanding its pathophysiology, effective management is hindered by the persistence knowledge gaps epidemiology, phenotypic heterogeneity and policy implementation. Materials Methods This consensus statement European Society for Clinical Investigation identifies eight critical areas requiring urgent attention. Key include insufficient long‐term data on trends, inadequacy body mass index (BMI) as sole diagnostic measure, recognition diversity obesity‐related cardiometabolic risks. Moreover, socio‐economic drivers transition across phenotypes poorly understood. Results The syndemic nature obesity, exacerbated globalization environmental changes, necessitates holistic approach integrating frameworks community‐level interventions. advocates leveraging emerging technologies, such artificial intelligence, to refine predictive models address variability. It underscores importance collaborative efforts among scientists, policymakers, stakeholders create tailored interventions enduring policies. Discussion highlights need harmonizing anthropometric biochemical markers, fostering inclusive narratives combating stigma obesity. By addressing these gaps, this initiative aims advance research, improve prevention strategies optimize care delivery people living Conclusion effort marks decisive step towards mitigating epidemic profound impact systems. Ultimately, should be considered being largely consequence model not compatible optimal human health.

Language: Английский

---

Comparative Efficacy of Lifestyle Modifications versus Pharmacotherapy on Weight Loss and Metabolic Health Outcomes: A Comprehensive Review

Journal of Biosciences and Medicines, Journal Year: 2024, Volume and Issue: 12(07), P. 17 - 29

Published: Jan. 1, 2024

Background: Obesity has become a serious global public health challenge, given that it leads to various adverse outcomes include cardiovascular illnesses, diabetes, and certain types of cancer. The World Health Organization (WHO) estimated that, at the end 2022, 1 out every 8 individuals were obese, adult obesity rates have over doubled since 1990, even as adolescent quadrupled. Thus, nearly 2.5 billion adults, aged 18 years above, overweight, with 890 million being obese. overweight incidence rate been gradually increasing years, presenting significant challenges healthcare systems throughout globe. In this regard, objective systematic review was evaluate effectiveness safety lifestyle modifications (diet physical activity) pharmacotherapy in promoting weight loss improving metabolic adults. Methodology: To attain above stated study objective, evaluation previous studies carried out, particularly assessed authors used Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRISMA) selection eligible inclusion study. Results: findings indicate interventions resulted 5% - 10% reduction improvements indicators, while (GLP-1 receptor agonists) achieved up 15% considerable benefits. Further, comparative show provide overall benefits, medication is necessary non-responders. Conclusion: Individualized treatment strategies are crucial, further research needed on long-term consequences combination therapies.

Language: Английский

---

ДІЄТИЧНІ СТРАТЕГІЇ ТА ЛІКУВАЛЬНО-ПРОФІЛАКТИЧНІ ПІДХОДИ ДО ВІДНОВЛЕННЯ ПОРУШЕНЬ РЕПРОДУКТИВНОЇ ФУНКЦІЇ У ЖІНОК ІЗ НАДМІРНОЮ МАСОЮ ТІЛА

Актуальні питання педіатрії акушерства та гінекології, Journal Year: 2024, Volume and Issue: 1, P. 25 - 30

Published: April 15, 2024

Мета дослідження – оптимізувати дієтичні стратегії та лікувально-профілактичні підходи до відновлення порушень репродуктивної функції у жінок із надмірною масою тіла. Матеріали методи. Проведено оцінку ефективності лікувально-профілактичної програми двох групах пацієнток тіла порушенням функції: в основній групі (50 пацієнток) запропоновано персоніфікований комплекс дієтичних стратегій медикаментозних засобів врахуванням коморбідності клінічних станів факторів ризику, а порівняння жінок) використовували загальноприйняті підходи. Застосовано методику використанням розробленого опитувальника антропометричне показників (маса, зріст, обвід талії стегон визначенням їх співвідношення, індекс маси тіла). Результати обговорення. Необхідно відмітити ефективність запропонованої терапії, що проявилося зменшенні вираження абдомінального ожиріння зниженні середньому на (12,2±3,3) кг (14,6 %), статистично достовірно від вихідного рівня. Спостерігали значне поліпшення ліпідного обміну, позитивну тенденцію щодо корекції гіпертригліцеридемії і нормалізацію рівня печінкових трансаміназ. У 70,0 % відмітили ритму характеру менструального циклу. Висновки. Комбінація стратегій, дозованого фізичного навантаження медикаментозного комплексу чинників ризику соматичної гінекологічної патології дозволила досягти через 6 місяців терапії зменшення ожиріння, зниження 14,6 %, також нормалізації

---

Percent Body Fat and Weight Status of Youth Participating in Pediatric Weight Management Programs in the Pediatric Obesity Weight Evaluation Registry

Childhood Obesity, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 26, 2024

Factors associated with change in percent body fat (%BF) of children pediatric weight management (PWM) care may differ from those status.

Language: Английский

---

Analysis of the Effectiveness and Safety of the Fentermine and Topiramate Association in Obesity: A Systematic Review of the Literature

Multidisciplinar, Journal Year: 2024, Volume and Issue: 3, P. 55 - 55

Published: Oct. 8, 2024

Introduction: obesity is a chronic disease that can manifest itself at any stage of life, with an increasing incidence and prevalence, which contributes to other health problems.Objective: determine the application Phentermine Topiramate in treatment obesity.Methods: search for clinical trials randomized controlled was conducted. The carried out exhaustively engines/databases PubMed, Cachrane Library, Scopus, Google Scholar Web Science. Results: 21 studies were identified, 11 met inclusion criteria. evaluated research articles provided moderate evidence combination effective safe obesity. A gradual decrease patients' body weight observed from start up 20 weeks thereafter. In addition, notable secondary outcomes, such as changes blood pressure, triglyceride levels, high-density lipoprotein (HDL) cholesterol, low-density (LDL) cholesterol glycosylated hemoglobin (A1C) found treatment.Conclusion: doses these drugs control adults are 3,75 mg, 7,5 mg 15 case phentermine 23 46 92 topiramate, being maximum recommended dose mg/92 mg. If 5 % loss not achieved after 12 this dose, their use should be reconsidered

Language: Английский

---

Obesity epidemic in European countries: from an unaddressed risk factor to a medicalized disease?

The European Journal of Health Economics, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 20, 2024

Language: Английский

---